Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CUPRIMINE vs ADDERALL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Wilson disease,Cystinuria,Rheumatoid arthritis (off-label)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Metabolized by oxidation and reduction; primarily renal elimination.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
~70% bound, primarily to serum albumin.
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
Vd: 0.5–1.0 L/kg (approximately 70 L in adults). Indicates distribution into total body water with moderate tissue binding.
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Oral: Approximately 40–70% (variable, reduced by food, especially high-protein meals; administration on empty stomach recommended).
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 25-50%. Monitor urinary copper and adjust accordingly.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to hepatotoxicity risk. Monitor liver function.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
10-20 mg/kg/day orally divided into 2-4 doses; typical starting dose 15 mg/kg/day for Wilson disease (max 1 g/day). Titrate based on urinary copper.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal decline; monitor renal function and copper levels.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
WARNING: CUPRIMINE can cause severe bone marrow depression leading to aplastic anemia, leukopenia, thrombocytopenia, and agranulocytosis. Deaths have occurred. Monitor blood counts closely.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Bone marrow suppression, renal toxicity (proteinuria, hematuria), lupus-like syndrome, myasthenia gravis-like syndrome, rash, and hypersensitivity reactions. Monitor renal function, blood counts, and urinalysis regularly.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
History of penicillamine-related aplastic anemia or agranulocytosis; concurrent gold therapy, antimalarial drugs, or immunosuppressants; rheumatoid arthritis patients with renal insufficiency.
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
Take on an empty stomach. Avoid food, especially milk, and any mineral supplements (iron, zinc, calcium) for at least 1 hour before and 2 hours after dosing, as they reduce absorption. Alcohol should be avoided due to potential hepatotoxicity.
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential for growth restriction. Third trimester: Risk of fetal copper deficiency and associated neurological impairment. Pregnancy category D.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
Excreted in breast milk. M/P ratio not established. Contraindicated in breastfeeding due to potential for severe adverse effects (hypersensitivity, bone marrow suppression) in the infant.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
No standard dose adjustment recommended; use lowest effective dose. Monitor serum copper to maintain therapeutic levels due to altered pharmacokinetics in pregnancy (increased volume of distribution, renal clearance).
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
Monitor for proteinuria and hematuria; perform urinalysis weekly initially, then monthly. Penicillamine can cause bone marrow suppression; obtain baseline CBC and differential, then monitor every 2 weeks for first 6 months, then monthly. Drug-induced lupus and myasthenia gravis are rare but serious autoimmune adverse effects. Avoid in patients with a history of penicillin allergy due to potential cross-sensitivity. Administer on an empty stomach at least 1 hour before or 2 hours after meals to enhance absorption. Dose adjustments needed in renal impairment. Pyridoxine (vitamin B6) supplementation (25-50 mg/day) is recommended to prevent deficiency caused by penicillamine. For Wilson disease, monitor 24-hour urinary copper excretion to guide therapy.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not skip doses; take exactly as prescribed and do not double up if a dose is missed.,Report any signs of allergy promptly: rash, itching, fever, joint pain, or swollen lymph nodes.,Contact your doctor immediately if you experience easy bruising, bleeding, or signs of infection such as fever or sore throat.,Inform your doctor about any planned vaccinations; avoid live vaccines while on this medication.,You may need regular blood and urine tests to monitor for side effects.,If you are taking iron supplements or other mineral supplements, take them at least 2 hours apart from this medication to prevent reduced absorption.,Use effective contraception if you are of childbearing age; this drug can harm an unborn baby.,Avoid alcohol as it may increase the risk of liver toxicity.,Notify your dentist about your medication history before any dental procedures.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CUPRIMINE vs ADDERALL 15, answered by our medical review team.
CUPRIMINE is a Chelating Agent that works by Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.. ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CUPRIMINE and ADDERALL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CUPRIMINE is: 250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.. The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CUPRIMINE and ADDERALL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CUPRIMINE is classified as Category C. First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential . ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.